An enzyme inhibitor that regulates insect larvae development reduces heart enlargement and irregular heart rhythms in a mouse model, a 16-member University of California, Davis research team has discovered. The work, published in the current edition of Proceedings of the National Academy of Sciences, could lead to important new medications to treat human heart patients.
News tips from the 2006 annual meeting of the American Society of Nephrology, Nov. 14 to 19, San Diego.
For African-Americans with high blood pressure, the combination of risk factors known as metabolic syndrome brings an increased risk of worsening kidney disease, reports a paper being presented at the American Society of Nephrology’s 39th Annual Meeting and Scientific Exposition in San Diego.
An observational study of more than 64,000 asthma patients demonstrated that patients receiving treatment with Advair Diskus (fluticasone propionate and salmeterol inhalation powder) had a significant risk reduction in emergency department visits due to asthma versus patients treated with fluticasone propionate (FP) alone.
Novartis announced today a positive opinion supporting European Union approval of Exforge? (valsartan/ amlodipine besylate) as a new treatment option for patients with high blood pressure.
Frequent bouts of depression, anxiety, hostility and anger are known to increase a person’s risk for developing coronary heart disease, but a combination of these “negative” personality traits may put people at especially serious risk, according to a study by researchers at Duke University Medical Center.
More than 20 million Americans suffer from diabetes, a serious, chronic illness. Now, during American Diabetes Month, everyone has an opportunity to make an impact in the fight against the disease, at no cost, with just a click of the mouse. For each visitor who clicks at www.Click4Diabetes.com, a donation will be made to the American Diabetes Association (ADA), the nation’s leading nonprofit health organization providing diabetes research, information and advocacy.
A device first implanted in the United States at the University of Rochester Medical Center as part of a clinical trial is showing a significant reduction in blood pressure in patients who suffer from severe hypertension and cannot control their condition with medications or lifestyle changes.
A study published in the October journal of Clinical and Applied Thrombosis/Hemostasis shows Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree reduced edema, a typical side effect of antihypertensive medications, by 36 percent in patients taking these medications.
About one-third of heart attack patients do not receive treatment to open blocked arteries within the recommended 12-hour timeframe after a heart attack. Treatment such as angioplasty or clot-busting drugs may not be given because patients arrive at the hospital too late.